Award Number: W81XWH-08-1-0728

TITLE: Developing Treatment, Treatment Validation, and Treatment Scope in the Setting of an Autism Clinical Trial

PRINCIPAL INVESTIGATOR: William G. Johnson, M.D.

CONTRACTING ORGANIZATION: UMDNJ-Robert Wood Johnson Medical School Piscataway, NJ 08854

REPORT DATE: October 2009

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
## 4. TITLE AND SUBTITLE
Developing Treatment, Treatment Validation, and Treatment Scope in the Setting of an Autism Clinical Trial

## 5a. CONTRACT NUMBER
W81XWH-08-1-0728

## 6. AUTHOR(S)
William G. Johnson, M.D.

Email: wjohnson@umdnj.edu

## 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
UMDNJ-Robert Wood Johnson Medical School
Piscataway, NJ 08854

## 14. ABSTRACT
During the 01 year we obtained IRB approval, designed primers as per task #8, and wrote and submitted a project for an NIH Center grant to extend this study. We obtained IRB approval on 12/07/09. Our approved protocol and supporting documents have been submitted to the Human Research Protection Office (HRPO), Office of Research Protections (ORP) of the DOD for review. We are also applying for a Certificate of Confidentiality (COC) from the Once we have approval from the Human Research Protection Office (HRPO), Office of Research Protections (ORP) of the DOD we will begin work on tasks 4 and 7. We will also begin work on task 6, 9, 10, 11, and 12 for the samples obtained from the AGRE Bank (since these samples will be received without PHI and therefore do not need a COC) but these tasks will not begin for the recruited study subjects until subject recruitment, enrollment and treatment have been completed. Task #8 was completed in early 2009 but we will re-assess our results since a significant amount of time has passed and there may be better SNP’s available at this time. Please see partnering projects W81XWH-08-1-0729 and W81XWH-08-1-0730.

## 15. SUBJECT TERMS
Annual, Report, Autism, Idea Award,
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>Body</td>
<td>5 - 9</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>9</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>9</td>
</tr>
<tr>
<td>Conclusion</td>
<td>9</td>
</tr>
<tr>
<td>References</td>
<td>10</td>
</tr>
<tr>
<td>Appendices</td>
<td>10</td>
</tr>
</tbody>
</table>
Introduction:

This project is to test to see if DHA treatment can beneficially affect excretion of urinary biomarkers of oxidative stress and the autism clinical phenotype. In addition polymorphic variants of genes of certain enzymes that synthesize and metabolize docosahexaenoic acid (DHA) may contribute to the phenotype of some autism cases. We will test to see if any of these genes are risk factors for autism. We will also measure changes in excretion of the polyunsaturated fatty acid (PUFA) derived biomarkers of oxidative stress (isoprostanes and neuroprostanes) together with the changes in production of anti-inflammatory lipid mediators. We will test these biomarkers to see if we can monitor and validate effectiveness of DHA therapy. We will also test the genotypes of key DHA-metabolizing enzymes can predict which patients will respond to therapy. Please see partnering projects W81XWH-08-1-0729 and W81XWH-08-1-0730.

Body:

Project 3: PI William Johnson, MD, Initiating PI, W81XWH-08-1-0728
Please see partnering projects W81XWH-08-1-0729 and W81XWH-08-1-0730.

Task #1 Obtain IRB approval (first 4-6 months of 01 year, W. Johnson).

The first year of the project has been used to obtain IRB approval from the UMDNJ-RWJMS IRB office. The major points in the timeline follow. In the course of this timeline numerous meetings took place with the IRB office, the Chairpersons of the three PI’s of this project, and the Research Dean in order to facilitate the process. In addition we consulted with a number of persons with expertise in the field.

Our initial submission to our IRB office was submitted on July 18th 2008. We received a de-briefing memo from our IRB on August 4th 2008 with twenty one suggestions and recommendations.

We responded to this memo on September 15th 2008. The IRB requested clarification to one of our responses. This clarification was sent in on November 5th, 2008. Our IRB offices were moved in the month of October 2008 and their review was not completed until November.

We received a “Notice of Approval with Stipulations” from the IRB on November 26th, 2008 and we received the stipulations themselves on December 5th, 2008. We responded to all four stipulations and sent the responses to the IRB on December 22nd, 2008. An expedited review was scheduled for January 9th, 2009. The reviewer decided that our response to the first stipulation (related to simplification of the language in the consent form) should be reviewed by a full committee. The committee met on January 30th, 2009 and we received the memo on February 6th, 2009. At this meeting our four responses were tabled, and 24 suggestions / recommended changes were sent to us, most of them completely new. One of these changes requested was that we obtain an IND for the use of DHA.

We responded to this by sending our IRB copies of documentation to support that an IND was not needed because 1.) an FDA letter dated May 17, 2001 to Martek (manufacturers of the DHA to be used) designated their DHA as “Generally Regarded as Safe” (GRAS) (please see
http://www.cfsan.fda.gov/~rdb/opa-g041.html and 2.) documentation from the FDA on their website www.clinicaltrials.gov (search for MARTEK and DHA) shows that none of the 10 current or completed studies that used Martek’s DHA had had an IND including one with subjects with autism (showing that our use was not a new indication). We responded to the other 23 new questions and submitted all this for review on February 27th, 2009.

We received the de-briefing memo on March 6th, 2009. The memo requested that we needed to get an IND from the FDA for the project and it contained 2 new additional requirements. First, our IRB wanted us to create a tissue bank for the storage of the samples. Second our IRB wanted us to apply for a Certificate of Confidentiality for this project before they would give full approval.

We convened a meeting with the Chair of the IRB, the IRB director and the PI’s on May 8th, 2009 to discuss each of their requirements.

The key outcomes of the meeting and our responses were as follows;
First, even though it is already considered General Regarded as Safe (GRAS) in children, we would nonetheless need either an IND for the use of Martek’s DHA or a letter from the FDA saying that one was not needed. We completed the application for the IND and we submitted it on July 16th, 2009 (available upon request, 298 pages). We received a letter from the FDA August 4th, 2009 exempting us from needing an IND.
Second, even though to our knowledge there is no federal or state rule or regulation requiring us to create a tissue bank and there was no university policy in place, a Tissue Bank Application, Protocol and Manual along with supporting documents would have to be submitted for this project. Upon receipt of the March 6th memo asking us to set up a tissue bank we decided to take two parallel tracks. The first was to write a Tissue Bank Application. The second was to present to the IRB that we would destroy the samples after the termination of the project, and if at that time there was future scientific use for the samples and a tissue bank was available we would amend the protocol and place the samples in a bank. We submitted a Tissue Bank application on May 24th 2009. We have since completely re-written the Tissue Bank Application, Protocol, Manual and supporting documents and are preparing to re-submit.

Third, our IRB told us that we must apply for a Certificate of Confidentiality (COC) before they would give us full approval. Prior IRB approval is a NIH requirement for submitting a COC application.

Additional submissions, responses and amendments.
The following dates represent requests for changes or requests for clarifications (to either the consent form, assent form, protocol, application or other supporting documentation) and subsequent replies by us;
Memo from the IRB May 29, 2009 Replied to on July 10th, 2009
Memo from the IRB September 1, 2009 Replied to on September 9th, 2009
Memo from the IRB September 30th, 2009 Replied to on October 19, 2009
Memo from the IRB November 20th, 2009 Replied to on December 5th, 2009

In addition there were 3 modifications to the protocol, all related to changes in study personnel between the time the grant was submitted and the time the study was approved.

We obtained IRB approval on December 7th 2009. Two important points. First our IRB office accepted the FDA’s letter stating that we do not need an IND. Second, our IRB office also
accepted our proposal to destroy the samples at the end of the project. We are continuing with the Tissue Bank application and once approved we will amend the protocol for this project to allow us to keep the samples by placing them into the Tissue Bank.

Our approved protocol and supporting documents have been submitted to the Human Research Protection Office (HRPO), Office of Research Protections (ORP) of the DOD for review. We are also in the process of applying for a Certificate of Confidentiality from the NIH as per our IRB requirements. No work will be done on the recruited subjects until we receive either a COC or a letter indicating we do not need one and we have approval from the Human Research Protection Office (HRPO), Office of Research Protections (ORP) of the DOD. Our IRB office will allow us to start work with the samples from the AGRE Bank before a COC has been obtained since these samples will be received without PHI.

Task #2 Obtain blood samples from 66 DHA-treated and 66 placebo-treated autism cases (total 132) from Project #1 (6-30 months, E. Stenroos).

This task will not begin until subject recruitment, enrollment and treatment have been completed. Please note, subjects will be obtained from partnering project W81XWH-08-1-0730.

Task #3 Aliquot blood samples, store them in the Laboratory of Molecular Neurogenetics freezers (6-30 months, E. Stenroos).

This task will not begin until subject recruitment, enrollment and treatment have been completed.

Task #4 Receive & organize DNA samples from the AGRE Repository (01 year, E. Stenroos).

This Task will begin as soon as we have received approval from the Human Research Protection Office (HRPO), Office of Research Protections (ORP) of the DOD. The samples from this bank will be received without PHI. Our IRB office will therefore allow us to start work with them before a COC has been obtained.

Task #5 Extract blood DNA from 132 new autism cases, 99 Neurogenetics autism trios (01 year for Neurogenetics samples, 6-30 months for 132 new autism cases, E. Stenroos).

This task will not begin until subject recruitment, enrollment and treatment have been completed.

Task #6 Organize and quantitate DNA samples from 132 new autism cases, 99 autism Neurogenetics trios & 592 AGRE trios, organize them for genotyping (01 year for Neurogenetics & AGRE samples, 6-30 months for new autism cases, E. Stenroos).

This Task will begin for samples from the AGRE Bank as soon as we have received approval from the Human Research Protection Office (HRPO), Office of Research Protections (ORP) of the DOD.
This task will not begin for the study subjects until subject recruitment, enrollment and treatment have been completed. This can not start until a COC is obtained or a letter from the NIH stating we do not need one.

**Task #7 Obtain & organize primers for full GSTM1*0 genotyping (01 year, E. Stenroos).**

This Task will begin as soon as we have received approval from the Human Research Protection Office (HRPO) Office of Research Protections (ORP) of the DOD.

**Task #8 Select, obtain & organize primers for SNPstream genotyping (01 year, E. Stenroos).**

This task is not related to human subjects work and we began this in March of 2008. We completed this but will re-asses since a significant amount of time has passed and there may be better SNP’s available at this time.

**Task #9 Prepare samples for GSTM1*0 Real Time PCR genotyping (6-30 months, E. Stenroos).**

This Task will begin for samples from the AGRE Bank as soon as we have received approval from the Human Research Protection Office (HRPO) Office of Research Protections (ORP) of the DOD
This task will not begin for the study subjects until subject recruitment, enrollment and treatment have been completed.

**Task #10 Prepare samples for SNPstream genotyping (6-30 months, E. Stenroos).**

This Task will begin for samples from the AGRE Bank as soon as we have received approval from the Human Research Protection Office (HRPO) Office of Research Protections (ORP) of the DOD
This task will not begin for the study subjects until subject recruitment, enrollment and treatment have been completed.

**Task #11 Genotype samples for GSTM1*0 using Real Time PCR (6-30 months, E. Stenroos, L. Shein, RWJMS DNA Core).**

This Task will begin for samples from the AGRE Bank as soon as we have received approval from the Human Research Protection Office (HRPO) Office of Research Protections (ORP) of the DOD
This task will not begin for the study subjects until subject recruitment, enrollment and treatment have been completed.

**Task #12 Genotype SNPs of genes related to DHA metabolism using SNPstream: AGRE trios, Neurogenetics trios & new autism cases (6-30 months, E. Stenroos & A. Brooks).**

This Task will begin for samples from the AGRE Bank as soon as we have received approval from the Human Research Protection Office (HRPO) Office of Research Protections (ORP) of the DOD
This task will not begin for the study subjects until subject recruitment, enrollment and treatment have been completed.
Task #13 Organize, clean & analyze GSTM1*0 genotypes from the 132 new autism cases and correlate them with level of isoprostane excretion, levels of excretion of other biomarkers of oxidative stress and clinical response to treatment (6-36 months, S. Buyske, T. Matise & E. Stenroos).

This task will begin when all relevant data have been obtained. Note, isoprostane excretion data will be from the partnering project W81XWH-08-1-0729.

Task #14 Organize, clean and analyze genotype data from DHA metabolism genes from autism trios (AGRE & Neurogenetics) and from 132 new autism cases and correlate these genotypes with autism, level of isoprostane excretion, levels of excretion of other biomarkers of oxidative stress and clinical response to treatment (6-30 months, S. Buyske, T. Matise & E. Stenroos).

This task will begin when all relevant data have been obtained.

Task #15 Manuscripts prepared and submitted for publication (03 year, all investigators).

This task will begin once all data have been analyzed.

Key Research Accomplishments
There are no Key Research Accomplishments yet.

Reportable Outcomes:
On May 29th we submitted a proposal and accompanying core as part of Dr. George Lambert’s NIH Center Grant titled “Children’s Environmental Health and Disease Prevention Research Centers (P01) “ ($7,800,000 total costs). Our submitted proposal is designed to utilize the samples collected in W81XWH-08-1-0728 as is required by the Center Grant RFA. We plan to test additional polymorphisms related to DHA metabolism and oxidative stress (no overlap with W81XWH-08-1-0728. We felt that this would be an important addition to the current project. The Center Grant was not funded.

Conclusion:
A large amount of time was spent on getting IRB approval for this project. We received a conditional IRB approval on December 7th 2009. The condition is to apply to NIH for a Certificate Of Confidentiality (COC). We have written a COC and plan on submitting it by the end of the week. We have also, submitted the approved protocol and supporting documents to the Human Research Protection Office (HRPO) Office of Research Protections (ORP) of the DOD for review. If the Human Research Protection Office (HRPO), Office of Research Protections (ORP) of the DOD requires no changes we will start recruiting subjects as soon as we have a COC. If changes must be made to the Protocol or supporting documents we will amend our protocol with our IRB and upon acceptance of the amendment by our IRB and receipt of the COC we will begin recruiting subjects (Please see partnering project W81XWH-08-1-0730).

As soon as we have approval from the Human Research Protection Office (HRPO) Office of Research Protections (ORP) of the DOD we will begin work on tasks 4, 7 and 8. We will also
begin work on task 6, 9, 10, 11 and 12 for the samples obtained from the AGRE Bank, since these samples will be received without PHI. These tasks will not begin for the study subjects until subject recruitment, enrollment and treatment have been completed. Please see partnering projects W81XWH-08-1-0729 and W81XWH-08-1-0730.

References:
There are no references.

Appendices:
There are no appendices.